

BVF PARTNERS L P/IL
Form 4
November 15, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BVF PARTNERS L P/IL

2. Issuer Name and Ticker or Trading Symbol
INFINITY PHARMACEUTICALS, INC. [INFI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
44 MONTGOMERY STREET, 40TH FLOOR

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2018

____ Director
____ Officer (give title below)
 10% Owner
____ Other (specify below)

(Street)
SAN FRANCISCO, CA 94104

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
____ Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, \$0.001 par value ⁽¹⁾	11/13/2018		P		41,454	A	\$ 1.35
Common Stock, \$0.001 par value ⁽¹⁾	11/13/2018		P		562,754	A	\$ 1.35
Common Stock, \$0.001 par	11/14/2018		P		117,290	A	\$ 1.34
							7,474,110
							5,683,853
							7,591,400
							D ⁽²⁾
							D ⁽³⁾
							D ⁽²⁾

value ⁽¹⁾

Common
Stock,
\$0.001 par
value ⁽¹⁾

11/14/2018

P

92,960 A

\$
1.34

5,776,813

D ⁽³⁾

Common
Stock,
\$0.001 par
value ⁽¹⁾

11/15/2018

P

52,400 A

\$
1.35

7,643,800

D ⁽²⁾

Common
Stock,
\$0.001 par
value ⁽¹⁾

11/15/2018

P

39,074 A

\$
1.35

5,815,887

D ⁽³⁾

Common
Stock,
\$0.001 par
value ⁽¹⁾

1,167,191

D ⁽⁴⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 6)
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
				Code	V (A) (D)				

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

X

BVF PARTNERS L P/IL
 44 MONTGOMERY STREET
 40TH FLOOR
 SAN FRANCISCO, CA 94104

BIOTECHNOLOGY VALUE FUND L P
 44 MONTGOMERY STREET X
 40TH FLOOR
 SAN FRANCISCO, CA 94104

BIOTECHNOLOGY VALUE FUND II LP
 44 MONTGOMERY STREET X
 40TH FLOOR
 SAN FRANCISCO, CA 94104

Biotechnology Value Trading Fund OS LP
 P.O. BOX 309 UGLAND HOUSE See Explanation of Responses
 GRAND CAYMAN, E9 KY1-1104

BVF Partners OS Ltd.
 P.O. BOX 309 UGLAND HOUSE See Explanation of Responses
 GRAND CAYMAN, E9 KY1-1104

BVF INC/IL
 44 MONTGOMERY STREET X
 40TH FLOOR
 SAN FRANCISCO, CA 94104

LAMPERT MARK N
 44 MONTGOMERY STREET X
 40TH FLOOR
 SAN FRANCISCO, CA 94104

Signatures

BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 11/15/2018
 **Signature of Reporting Person Date

Biotechnology Value Fund, L.P., By: BVF Partners L.P., its general partner, By: BVF Inc.,
 its general partner, By: /s/ Mark N. Lampert, President 11/15/2018
 **Signature of Reporting Person Date

Biotechnology Value Fund II, L.P., By: BVF Partners L.P., its general partner, By: BVF Inc.,
 its general partner, By: /s/ Mark N. Lampert, President 11/15/2018
 **Signature of Reporting Person Date

BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general
 partner, By: /s/ Mark N. Lampert, President 11/15/2018
 **Signature of Reporting Person Date

Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager,
 BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 11/15/2018
 **Signature of Reporting Person Date

BVF Inc., By: /s/ Mark N. Lampert, President

11/15/2018

__Signature of Reporting Person

Date

/s/ Mark N. Lampert

11/15/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and

(1) Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

(2) Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

(3) Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

(4) OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.